Prophylactic efficacy of riluzole against anxiety- and depressive-like behaviors in two rodent stress models
Y. Bansal, C. Fee, K. Misquitta, S. A.-M. Codeluppi, E. Sibille, R. Berman, V. Coric, G. Sanacora, M. Banasr
Abstract
BackgroundChronic stress-related illnesses, such as major depressive disorder and post-traumatic stress disorder share symptomatology, including anxiety, anhedonia, and helplessness. Across disorders, neurotoxic dysregulated glutamate (Glu) signaling may underlie symptom emergence. Current first-line antidepressant drugs, which do not directly target Glu signaling, fail to provide adequate benefit for many patients and are associated with high relapse rates. Riluzole modulates glutamatergic neurotransmission by increasing metabolic cycling and modulating signal transduction. Clinical studies exploring riluzoles efficacy in stress-related disorders have provided varied results. However, the utility of riluzole for treating specific symptom dimensions or as a prophylactic treatment has not been comprehensively assessed. MethodsWe investigated whether chronic prophylactic riluzole (~12-15mg/kg/day p.o.) could prevent the emergence of behavioral deficits induced by unpredictable chronic mild stress (UCMS) in mice. We assessed: i) anxiety-like behavior using the elevated-plus maze, open field test, and novelty-suppressed feeding, ii) mixed anxiety/anhedonia-like behavior in the novelty-induced hypophagia test and, iii) anhedonia-like behavior using the sucrose consumption test. Z-scoring summarized changes across tests measuring similar dimensions. In a separate learned helplessness (LH) cohort, we investigated whether chronic prophylactic riluzole treatment could block the development of helplessness-like behavior. ResultsUCMS induced an elevation in anhedonia-like behavior, and overall behavioral emotionality that was blocked by prophylactic riluzole. In the LH cohort, prophylactic riluzole blocked the development of helplessness-like behavior. ConclusionThis study supports the utility of riluzole as a prophylactic medication for preventing anhedonia, and helplessness symptoms associated with stress-related disorders.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Administration of the glutamate-modulating drug riluzole after stress reverses its delayed effects on the amygdala
Siddhartha Datta, Zubin Rashid, … Sumantra Chattarji·bioRxiv·Mar 8, 2023
- Prophylactic efficacy of 5-HT4R agonists against stress
Briana K. Chen, Indira Mendez‐David, … Christine Ann Denny·NeuropsychopharmacologyPeer-reviewed·Oct 10, 2019
- Residual avoidance: a new consistent and repeatable readout of chronic stress-induced conflict anxiety reversible by antidepressant treatment
T. D. PREVOT, K. A. Misquitta, … M. Banasr·bioRxiv·May 6, 2019
- Disrupted neuropeptide-signaling drives enduring reward deficits after early-life stress
Matthew T. Birnie, Lara Taniguchi, … Tallie Z. Baram·bioRxiv·Aug 27, 2026
- Chronic corticosterone administration induces negative valence and impairs positive valence behaviors in mice
Andrew Dieterich, Prachi Srivastava, … Benjamin Adam Samuels·Translational PsychiatryPeer-reviewed·Dec 10, 2019
- Fluoxetine treatment prevents cardiovascular changes in baroreflex and chemoreflex in rats subjected to chronic stress
E. M. S. Firmino, L. B. Kuntze, … L. B. M. Resstel·bioRxiv·Mar 4, 2020